RxDoctor Payments Data

Sakinah Shaw

Psychiatric/Mental Health · Hot Springs, ARNPI 1437856820

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (55.9%), speaking fees and education — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by AbbVie at 54.0% of the total. 2025 is the largest year on record at $5,414, 7.6 times the $713 reported in 2023. Among psychiatric/mental health clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,641in general payments, 2019–2025

Across 232 payments — averaging $32.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Supernus Pharmaceuticals, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$447
  • Teva Pharmaceuticals USA, Inc.$383
  • E.r. Squibb & Sons, L.L.C.$110
  • plus $418 from 8 others

What the payments were for

  • Speaking & faculty fees$3,00039%
  • Travel & lodging$1492%
  • Food & beverage$4,26956%
  • Education$2233%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,641 in reported general payments places this provider in the 95th percentile of 359 psychiatric/mental health providers in Arkansas.

See all psychiatric/mental health providers in Arkansas

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl31$44,218
RexultiBrexpiprazole24$37,660
Aripiprazole48$2,502
Lurasidone Hcl11$1,160
Atomoxetine Hcl12$871
Buspirone Hcl59$724
Oxcarbazepine19$675
Fluoxetine Hcl64$518
Prazosin Hcl37$444
Venlafaxine Hcl ErVenlafaxine Hcl34$436
Quetiapine Fumarate34$329
Bupropion XlBupropion Hcl20$319
Olanzapine27$310
Benztropine Mesylate30$297
Duloxetine Hcl24$272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$4,126$44,21831 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,041$37,66024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 359 psychiatric/mental health providers in Arkansas.

Other psychiatric/mental health in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →